DOCSLIB.ORG

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer cancers Review Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer Silvia Mezi 1 , Andrea Botticelli 2, Giulia Pomati 3,*, Bruna Cerbelli 1, Simone Scagnoli 4 , Sasan Amirhassankhani 5, Giulia d’Amati 1 and Paolo Marchetti 2 1 Department of Radiological, Oncological and Pathological Science, University of Rome “Sapienza”, 00185 Rome, Italy; [email protected] (S.M.); [email protected] (B.C.); [email protected] (G.d.) 2 Department of Clinical and Molecular Medicine, University of Rome “Sapienza”, 00185 Rome, Italy; [email protected] (A.B.); [email protected] (P.M.) 3 Department of Molecular Medicine, University of Rome “Sapienza”, 00185 Rome, Italy 4 Department of Medical and Surgical Sciences and Translational Medicine, University of Rome “Sapienza”, 00185 Rome, Italy; [email protected] 5 Department of Plastic Surgery, Guy’s & St Thomas’ NHS Foundation Trust, London SE1 7EH, UK; [email protected] * Correspondence: [email protected]; Tel.: +39-340-348-7850 Simple Summary: Mesenchymal triple negative breast cancer subtype expresses genes involved in proliferation, epithelial to mesenchymal transition, stromal interaction and cell motility. Moreover, this subgroup is characterized by an immunosuppressive microenvironment. This review focuses on the intracellular pathways involved in tumorigenesis and cancer progression, as well as in the immune evasion mechanisms. Furthermore, we provide an overview of current clinical trials investigating the efficacy and safety of different therapeutic molecules for this aggressive subtype Citation: Mezi, S.; Botticelli, A.; of triple negative breast cancer. The challenge is to restore immunocompetence by overcoming the Pomati, G.; Cerbelli, B.; Scagnoli, S.; chemo and immune-resistance profile of mesenchymal triple negative breast cancer to achieve a Amirhassankhani, S.; d’Amati, G.; lasting response to therapy. Marchetti, P. Standard of Care and Promising New Agents for the Abstract: The pathologic definition of triple negative breast cancer (TNBC) relies on the absence of ex- Treatment of Mesenchymal pression of estrogen, progesterone and HER2 receptors. However, this BC subgroup is distinguished Triple-Negative Breast Cancer. by a wide biological, molecular and clinical heterogeneity. Among the intrinsic TNBC subtypes, the Cancers 2021, 13, 1080. https:// mesenchymal type is defined by the expression of genes involved in the epithelial to mesenchymal doi.org/10.3390/cancers13051080 transition, stromal interaction and cell motility. Moreover, it shows a high expression of genes in- volved in proliferation and an immune-suppressive microenvironment. Several molecular alterations Received: 7 January 2021 Accepted: 25 February 2021 along different pathways activated during carcinogenesis and tumor progression have been outlined Published: 3 March 2021 and could be involved in immune evasion mechanisms. Furthermore, reverting epithelial to mes- enchymal transition process could lead to the overcoming of immune-resistance. This paper reviews Publisher’s Note: MDPI stays neutral the current knowledge regarding the mesenchymal TNBC subtype and its response to conventional with regard to jurisdictional claims in therapeutic strategies, as well as to some promising molecular target agents and immunotherapy. published maps and institutional affil- The final goal is a tailored combination of cytotoxic drugs, target agents and immunotherapy in order iations. to restore immunocompetence in mesenchymal breast cancer patients. Keywords: triple negative; breast cancer; mesenchymal subtype; immunotherapy; target therapy Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article 1. Introduction distributed under the terms and The management of breast cancer (BC), the most common tumor in women [1] has conditions of the Creative Commons improved since its sub-classification based on the expression of estrogen (ER), progesterone Attribution (CC BY) license (https:// receptors (PR) [2] and human epidermal growth factor receptor-2 (HER2) [3]. Four main creativecommons.org/licenses/by/ molecular subtypes of BC have been identified so far, based on the analysis of its global 4.0/). Cancers 2021, 13, 1080. https://doi.org/10.3390/cancers13051080 https://www.mdpi.com/journal/cancers Cancers 2021, 13, x 2 of 24 Cancers 2021, 13, 1080 2 of 24 main molecular subtypes of BC have been identified so far, based on the analysis of its global gene expression: Luminal A, luminal B, HER2, basal-like, and the more recently geneidentified expression: claudin-lo Luminalw tumor A, luminal subtype B, [4,5]. HER2, basal-like, and the more recently identified claudin-lowTriple negative tumor subtype breast cancer [4,5]. (TNBC) is defined by the lack of expression of ER, PR and HER2Triple and negative accounts breast for cancer about (TNBC)10–20% of is definedBCs [6]. byThis the definition lack of expression of TNBC is, of howev- ER, PR ander, limiting HER2and and accounts does not for allow about for 10–20% understa ofnding BCs [ 6its]. Thisheterogeneou definitions ofclinical TNBC behavior. is, how- ever,Based limiting on gene and expression does not profiling, allow for TNBCs understanding were originally its heterogeneous divided by Lehmann clinical behavior. into six Baseddifferent on subtypes: gene expression Basal-like profiling, 1 (BL1), TNBCs basal-like were 2 (BL2), originally immunomodulatory divided by Lehmann (IM), mes- into sixenchymal-like different subtypes: (M), mesenchymal Basal-like 1stem (BL1), cell-l basal-likeike (MSL) 2 (BL2), and luminal immunomodulatory androgen receptor (IM), mesenchymal-like(LAR). Both M and (M), MSL mesenchymal subtypes express stem cell-like genes (MSL)involved and in luminal the epithelial androgen to receptor mesen- (LAR).chymal Both transition M and (ETM), MSL subtypes stromal express interact genesion and involved cell motility. in the epithelial Moreover, to mesenchymal the M sub- transitiongroup displays (ETM), a stromalhigher interactionexpression andof genes cell motility. involved Moreover, in proliferation, the M subgroup while the displays MSL amore higher frequently expression shows of genesexpression involved of genes in proliferation, associated with while cell the stemness MSL more [5,7]. frequently Further showsstudies expression revealed that of genes the IM associated and MSL with subtypes cell stemness were strongly [5,7]. Further influenced studies by revealed the contri- that thebution IM andof transcripts MSL subtypes from were normal strongly stroma influenced and immune by the cells contribution of the tumor of transcripts microenviron- from normalment, respectively. stroma and immuneThus, the cells classification of the tumor hasmicroenvironment, been refined in therespectively. following 4 Thus,subtypes: the classificationBL1, BL2, M and has beenLAR refined[7–9]. The in thecomplexity following of 4 the subtypes: TNBC BL1,classification BL2, M and is also LAR determined [7–9]. The complexityby the possibility of the TNBCof identification classification of more is also than determined one subgroup by the in possibility some histological of identification types: ofFor more example, than onemetaplastic subgroup breast in some carcinoma histological could types: belong For to example, either the metaplastic BL2 or the breast M sub- car- cinomatype of couldBCs. Predominantly, belong to either themetaplastic BL2 or the tu Mmor subtype cells ofare BCs. pleomorphic Predominantly, and arranged metaplastic in tumor cells are pleomorphic and arranged in solid nests (Figure1A). The epithelial cells solid nests (Figure 1A). The epithelial cells shows a diffuse positivity for the mesenchy- shows a diffuse positivity for the mesenchymal marker vimentin on immunohistochemical mal marker vimentin on immunohistochemical staining (Figure 1B) staining (Figure1B). FigureFigure 1.1.Metaplastic Metaplastic breast breast carcinoma. carcinoma. (A ()A Tumor) Tumor cells cells are are highly highly pleomorphic pleomorphic and and arranged arranged in solid in solid nests. nests. (B) Immuno- (B) Im- histochemistrymunohistochemistry shows shows a diffuse a diffuse positivity positivity of neoplastic of neoplastic cells for cells the for mesenchymal the mesenchymal marker marker vimentin. vimentin. For the last two decadesdecades chemotherapy has been the onlyonly therapeutictherapeutic option,option, inin thethe absence ofof aa druggable druggable target. target. It playedIt played a central a central role inrole the in treatment the treatment of TNBC of inTNBC all disease in all settings,disease settings, even though even eachthough TNBC each subtype TNBC hassubt aype different has a different response response pattern to pattern the available to the chemotherapyavailable chemotherapy regimens [10regime]. Genens expression[10]. Gene analysis expression may an alsoalysis influence may chemotherapyalso influence treatmentchemotherapy choices; treatment a randomized choices; phase a randomiz III trial wased phase performed III trial comparing was performed use of carboplatincomparing vs.use docetaxelof carboplatin in unselected vs. docetaxel advanced in unselected TNBC and advanced in a priori TNBC specified and in biomarker a priori specified defined sub-populationsbiomarker defined [11 ].sub-populati In the unselectedons [11]. TNBC In patientthe unselected population, TNBC carboplatin patient was population, not more activecarboplatin compared
Load more

Recommended publications
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 45: 279-297, 2020 Precision medicine for human cancers with Notch signaling dysregulation (Review) MASUKO KATOH1 and MASARU KATOH2 1M & M PrecMed, Tokyo 113-0033; 2Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan Received September 16, 2019; Accepted November 20, 2019 DOI: 10.3892/ijmm.2019.4418 Abstract. NOTCH1, NOTCH2, NOTCH3 and NOTCH4 are conjugate (ADC) Rova-T, and DLL3-targeting chimeric antigen transmembrane receptors that transduce juxtacrine signals of receptor‑modified T cells (CAR‑Ts), AMG 119, are promising the delta-like canonical Notch ligand (DLL)1, DLL3, DLL4, anti-cancer therapeutics, as are other ADCs or CAR-Ts targeting jagged canonical Notch ligand (JAG)1 and JAG2. Canonical tumor necrosis factor receptor superfamily member 17, Notch signaling activates the transcription of BMI1 proto-onco- CD19, CD22, CD30, CD79B, CD205, Claudin 18.2, fibro- gene polycomb ring finger, cyclin D1, CD44, cyclin dependent blast growth factor receptor (FGFR)2, FGFR3, receptor-type kinase inhibitor 1A, hes family bHLH transcription factor 1, tyrosine-protein kinase FLT3, HER2, hepatocyte growth factor hes related family bHLH transcription factor with YRPW receptor, NECTIN4, inactive tyrosine-protein kinase 7, inac- motif 1, MYC, NOTCH3, RE1 silencing transcription factor and tive tyrosine-protein kinase transmembrane receptor ROR1 transcription factor 7 in a cellular context-dependent manner, and tumor-associated calcium signal transducer 2. ADCs and while non-canonical Notch signaling activates NF-κB and Rac CAR-Ts could alter the therapeutic framework for refractory family small GTPase 1. Notch signaling is aberrantly activated cancers, especially diffuse-type gastric cancer, ovarian cancer in breast cancer, non-small-cell lung cancer and hematological and pancreatic cancer with peritoneal dissemination.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance
    biomedicines Review Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance Marta Araujo-Castro 1,* , Eider Pascual-Corrales 1 , Javier Molina-Cerrillo 2 and Teresa Alonso-Gordoa 2 1 Neuroendocrinology Unit, Endocrinology and Nutrition Department, Ramón y Cajal Health Research Institute (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] 2 Medical Oncology Department, Ramón y Cajal Health Research Institute (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] (J.M.-C.); [email protected] (T.A.-G.) * Correspondence: [email protected] Abstract: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options in the advanced stages. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in advanced ACC has been investigated in different studies. With the aim clarifying the role of immunotherapy in ACC we performed a comprehensive review about this topic focusing on the predictors of response, efficacy, safety, and the mechanisms of resistance. Five clinical trials with four immune checkpoint inhibitors (pembrolizumab, avelumab, nivolumab, and ipilimumab) have investigated the role of immunotherapy in advanced ACC. Despite, the different primary endpoints used in these studies, the reported rates of overall response rate and progression free survival were generally poor. Three main potential markers of response to immunotherapy Citation: Araujo-Castro, M.; in ACC have been described: Expression of PD-1 and PD-L1, microsatellite instability and tumor Pascual-Corrales, E.; Molina-Cerrillo, mutational burden. However, none of them has been validated in prospective studies. Several J.; Alonso-Gordoa, T.
    [Show full text]
  • 353 Safety and Efficacy of Tumor Infiltrating Lymphocytes (TIL, LN-145
    Abstracts J Immunother Cancer: first published as 10.1136/jitc-2020-SITC2020.0353 on 9 November 2020. Downloaded from Methods IPI-549-01 (NCT02637531) evaluates eganelisib in advanced solid tumors, as monotherapy and in combination with nivolumab. The combination expansion dose was eganeli- sib 40 mg QD PO + nivolumab 240 mg Q2W IV. Combina- tion expansion cohorts include SCCHN patients resistant to immediate prior anti-PD(L)1 therapy. Safety, preliminary clini- cal activity, PK, and correlative study of blood and tumor biopsy samples were mandated. Results As of June 1, 2020, 180 patients were treated with eganelisib + nivolumab including 21 with SCCHN.The most common (>20% of patients) treatment-emergent adverse Abstract 353 Figure 1 Iovance LN-145 (autologous TIL cell therapy events in patients treated with eganelisib + nivolumab (N = product) Manufacturing 180) were fatigue (34.4%), increased AST (30.0%), increased ALT (26.7%), nausea (25.0%), pyrexia (25.0%), anemia (22.8%), decreased appetite (20.6%), and cough (20.6%). 85 (47.2%) patients experienced at least 1 treatment-emergent serious adverse event (SAE) and 19 (10.6%) had a treatment- related SAE. There were no treatment-related grade 5 adverse events as assessed by investigators. Preliminary data from the SCCHN cohort show that in the efficacy-evaluable population which includes all patients (n=20) who had at least 1 post- baseline response assessment or discontinued treatment due to disease progression, the overall response rate (ORR, ie. CR Abstract 353 Figure 2 IOV-COM-202 Study Schema [complete response] or PR [partial response] per RECIST v1.1) is 10.0%, the disease control rate (DCR, ie.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Perspectives in Immunotherapy: Meeting Report from the Immunotherapy Bridge (December 2Nd–3Rd, 2020, Italy) Paolo A
    Ascierto et al. J Transl Med (2021) 19:238 https://doi.org/10.1186/s12967-021-02895-2 Journal of Translational Medicine MEETING REPORT Open Access Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) Paolo A. Ascierto1* , Carlo Bifulco2, Fortunato Ciardiello3, Sandra Demaria4,5,6, Leisha A. Emens7,8, Robert Ferris8, Silvia C. Formenti9, Jerome Galon10,11,12, Samir N. Khleif13, Tomas Kirchhof14, Jennifer McQuade15, Kunle Odunsi16,17, Akash Patnaik18, Chrystal M. Paulos19, Janis M. Taube20, John Timmerman21, Bernard A. Fox22, Patrick Hwu23 and Igor Puzanov24 Abstract Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with diferent tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a signifcant proportion of patients still fail to beneft from current immunotherapy options, and ongoing research is focused on transforming non-responders to respond- ers through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identifcation of biomarkers of response. These topics were the focus of the virtual Immunother- apy Bridge (December 2nd–3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Gastrointestinal Cancer Tumor Panel
    POST-TEST Gastrointestinal Cancer Tumor Panel: Clinical Investigators Provide Their Perspectives on Current Cases and Clinical Issues in the Management of Colorectal, Gastric and Pancreatic Cancer THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. The Phase III TML trial evaluating 5. The results from the Phase III bevacizumab beyond disease progression RECOURSE trial of TAS-102 for patients for patients with metastatic colorectal with metastatic colorectal cancer cancer demonstrated a statistically refractory to standard therapies demon- significant improvement in overall strated a statistically significant improve- survival (OS) with bevacizumab beyond ment in ___________ with TAS-102/best progression compared to chemotherapy supportive care compared to placebo/ alone. best supportive care. a. True a. OS b. False b. Progression-free survival c. Both a and b 2. Similar to those with other agents in d. Neither a nor b the same class, the adverse events of note that were associated with the VEGF 6. Results from the Phase II RECAP trial inhibitor ramucirumab on the RAISE trial of capecitabine in combination with include ___________. ___________ or placebo as second-line a. Bleeding/hemorrhage therapy for patients with metastatic b. Hypertension pancreatic cancer indicated improved c. Proteinuria OS with that agent in a subgroup of d. Both a and b patients with high C-reactive protein levels. e. All of the above a. Ruxolitinib 3. The ongoing Phase III JACOB trial is b. Brivanib evaluating chemotherapy/trastuzumab c. Nanoparticle albumin-bound (nab) with or without ___________ as first-line paclitaxel therapy for patients with HER2-positive metastatic gastric or gastroesophageal- 7.
    [Show full text]
  • High Delta-Like Ligand 4 Expression Correlates with a Poor Clinical
    Journal of Cancer 2019, Vol. 10 3172 Ivyspring International Publisher Journal of Cancer 2019; 10(14): 3172-3178. doi: 10.7150/jca.30257 Research Paper High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer Youjin Kim1,2*, Sun-ju Byeon3,4*, Joonyoung Hur1, Kangkook Lee1, Dongin Kim5, Jin-Hyung Ahn5, Sang Hoon Lee5, Weon-Kyoo You5, Seung Tae Kim1, Se Hoon Park1, Won Ki Kang1, Kyoung-Mee Kim3, Jeeyun Lee1 1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2. Division of Hematology-Oncology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea 3. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 4. Department of Pathology, Hallym University Dongtan Sacred Heart Hospital, Korea 5. ABL Bio, Korea *Equal contributing authors Corresponding authors: Jeeyun Lee, MD, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351 (Korea). Tel. +82 2 3410 1779; Fax +82 2 3410 1754; Email: [email protected] and Kyoung-Mee Kim, MD, Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351 (Korea). Tel. +82 2 3410 2807; Fax +82 2 3410 1754; Email: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/).
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • ABOUT the TEST: PATIENT RESULTS TUMOR TYPE: BREAST CARCINOMA (NOS) Genomic Alterations Identified† Additional Findings† THER
    Patient Name Report Date Tumor Type Breast carcinoma (NOS) Date of Birth Medical Facility Sex Female Ordering Physician Specimen Received FMI Case # Additional Recipient Specimen Site Lung Medical Record # Medical Facility ID # Date of Collection Specimen ID Pathologist Specimen Type ABOUT THE TEST: FoundationOne™ is a next-generation sequencing (NGS) based assay that identifies genomic alterations within hundreds of cancer-related genes. PATIENT RESULTS TUMOR TYPE: BREAST CARCINOMA (NOS) 20 genomic findings Genomic Alterations Identified† ERBB2 R678Q 13 therapies associated with potential clinical benefit ⧺ ⧺ PIK3CA H1047R – subclonal , N1044K, R88Q – subclonal , V344M – subclonal⧺ 0 therapies associated with lack of response TSC1 L203fs*7 ARID1A splice site 2420-2A>G 34 clinical trials ASXL1 G645fs*58 LZTR1 Q10fs*24 MLH1 S446fs*32, V267fs*1 MLL2 A1105fs*14 MSH2 A230fs*16 NOTCH3 A2233fs*9 PPP2R1A R183W – subclonal⧺ RAD50 N934fs*6 SETD2 R1492* SMARCA4 R1157W Additional Findings† Microsatellite status MSI-High Tumor Mutation Burden TMB-High; 26 Muts/Mb † For a complete list of the genes assayed and performance specifications, please refer to the Appendix ⧺ See Appendix for details THERAPEUTIC IMPLICATIONS Genomic Findings FDA-Approved Therapies FDA-Approved Therapies Potential Clinical Trials Detected (in patient’s tumor type) (in another tumor type) ERBB2 Ado-trastuzumab emtansine Afatinib Yes, see clinical trials R678Q Lapatinib section Neratinib Pertuzumab Trastuzumab For more comprehensiveSAMPLE information please log on to the Interactive Cancer Explorer™ To set up your Interactive Cancer Explorer account, contact your sales representative or call 1-888-988-3639. Electronically Signed by Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 / CLIA:34D2044309 Foundation Medicine, Inc.
    [Show full text]